Last updated on November 2017

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease


Brief description of study

GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

Detailed Study Description

The purpose of this study is to evaluate itacitinib or placebo in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).

Clinical Study Identifier: TX14141

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Onclology Hematology in Cincinnati

Onclology Hematology in Cincinnati
Cincinnati, OH USA
  Connect »

Sarah Cannon Research Institute, LLC

Sarah Cannon Research Institute, LLC
Nashville, TN USA
  Connect »

Colorado Blood Cancer Institute

Colorado Blood Cancer Institute
Denver, CO USA
  Connect »

University of Chicago

University of Chicago
Chicago, IL USA
  Connect »

Massachusetts General Hospital

Massachusetts General Hospital
Boston, MA USA
  Connect »

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Boston, MA USA
  Connect »

Texas Transplant Institute

Texas Transplant Institute
San Antonio, TX USA
  Connect »

Tulane University Medical Center

Tulane University Medical Center
New Orleans, LA USA
  Connect »

University of Mississippi Medical Center

University of Mississippi Medical Center
Jackson, MS USA
  Connect »

Stony Brook University

Stony Brook University
Stony Brook, NY USA
  Connect »

UPMC Hillman Cancer Center

UPMC Hillman Cancer Center
Pittsburgh, PA USA
  Connect »